Market research
NTR.F Spectrum Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 193M
- P/E ratio
- Not available
- Analyst target
- 6.2
- Dividend yield
- 0.0%
- Beta
- 2.15
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US84763A1088
- Market cap
- 193M
- P/E ratio
- Not available
- Analyst target
- 6.2
- Dividend yield
- 0.0%
- Beta
- 2.15
About
About Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. As of July 31, 2023, Spectrum Pharmaceuticals, Inc. operates as a subsidiary of Assertio Holdings, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NTR.F discussion.
5 years, 4 months ago
Spectrum Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 2.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Spectrum Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1.5% to $-40M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.2% to $-35M since the same quarter in the previous year.
Based on the above factors, Spectrum Pharmaceuticals, Inc gets an overall score of 2/5.